What is the maximum plasma level of tamoxifen that can be achieved in breast cancer patients?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
The risk is so low that it is impossible to read using tables of published health data and statistics. Children do get cancer, but very rarely breast cancer. Statistics will often group women aged 15–39 as “young women” but this is very misleading as the bump in cases begins in women over 20, or eve....
This is one of those 'beliefs' that pop up from time to time. There is no proven link between deodorant use and breast cancer. Any studies completed to date have not been adequate to show proof. There are lots of things that are believed to cause cancer and very few of them have been proven because ....
A new treatment for breast cancer has completely eradicated tumours in just 11 days. A team of researchers in the UK claims the new two-pronged technique could spare thousands of women from gruelling chemotherapy. Doctors combined two existing cancer drugs - Tyverb and Herceptin – and gave them t....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Mithun Kumar
Tamoxifen is a highly effective endocrine treatment for breast cancer in the adjuvant and metastatic settings. Data from several large randomized clinical trials indicate that tamoxifen is also valuable in the prevention of breast cancer in women at high risk for the disease. However, not all women benefit from tamoxifen, and the side effect profiles vary considerably from patient to patient.
Tamoxifen treatment promotes significant changes both in the plasma concentration of an important marker associated with an increased risk of Cardio Vascular Disease (CVD) and in functional parameters of cardiac performance in women with breast cancer who have previously undergone chemotherapy. Previous studies had also confirmed the cardiotoxic effects of chemotherapy.
Chronic use of tamoxifen significantly reduces the plasma concentrations of CVD biomarkers (CRP, Apo B, and the Apo-B/Apo-A ratio) in women with breast cancer who underwent chemotherapy. Several study suggests the need for a careful cardiovascular evaluation and the medical monitoring of women with breast cancer to reduce the morbidity and mortality associated with cancer treatment complications.